The studies on Silymarin are currently in contrast.

Some do not attribute a significant role to Silymarin, as regards its hepatoprotective efficacy (1).

The flavolignans in Silymarin can be useful agents for protecting the skin against the harmful effects of solar radiation (2).

A randomized, triple-blind, placebo-controlled clinical trial concluded that oral administration of silymarin could significantly reduce the severity of hepatotoxicity after 1 month of treatment in patients with nonmetastatic breast cancer treated with an AC-T regimen (3).

References_____________________________________

(1) Wu S., Xia Y., Lv X., et al. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients. Journal of Gastroenterology and Hepatology. 2015;30(3):540–545. doi: 10.1111/jgh.12717.

(2) Skin Protective Activity of Silymarin and its Flavonolignans.
Vostálová J, Tinková E, Biedermann D, Kosina P, Ulrichová J, Rajnochová Svobodová A.
Molecules. 2019 Mar 14;24(6). pii: E1022. doi: 10.3390/molecules24061022

(3) Moezian GSA, Javadinia SA, Sales SS, Fanipakdel A, Elyasi S, Karimi G. Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial. J Oncol Pharm Pract. 2021 Apr 16:10781552211006182. doi: 10.1177/10781552211006182.